Cargando…

Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and it is anticipated that it could become even more prevalent in parallel with an increase in the incidence of metabolic diseases closely related to NAFLD, such as obesity, type II diabetes, dyslipidemia, and arteri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tripodi, Armando, Lombardi, Rosa, Primignani, Massimo, La Mura, Vincenzo, Peyvandi, Flora, Fracanzani, Anna L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869363/ https://www.ncbi.nlm.nih.gov/pubmed/35203457 http://dx.doi.org/10.3390/biomedicines10020249

Ejemplares similares

Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
por: Zarghamravanbakhsh, Paria, et al.
Publicado: (2021)

Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis
por: Panigada, Mauro, et al.
Publicado: (2020)

Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease
por: Lombardi, Rosa, et al.
Publicado: (2020)

Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction
por: Valenti, Luca, et al.
Publicado: (2022)

Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin
por: Pisano, Giuseppina, et al.
Publicado: (2016)

Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy
por: La Mura, Vincenzo, et al.
Publicado: (2023)

Hypercoagulability and the risk of recurrence in young women with myocardial infarction or ischaemic stroke: a cohort study
por: Maino, Alberto, et al.
Publicado: (2019)

An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians
por: Cespiati, Annalisa, et al.
Publicado: (2023)

Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2018)

Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kosmalski, Marcin, et al.
Publicado: (2022)

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
por: Rong, Li, et al.
Publicado: (2023)

Hypercoagulability Is a Stronger Risk Factor for Ischaemic Stroke than for Myocardial Infarction: A Systematic Review
por: Maino, Alberto, et al.
Publicado: (2015)

Simvastatin Prevents Liver Microthrombosis and Sepsis Induced Coagulopathy in a Rat Model of Endotoxemia
por: La Mura, Vincenzo, et al.
Publicado: (2022)

PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease
por: Lombardi, Rosa, et al.
Publicado: (2022)

In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kanuri, Giridhar, et al.
Publicado: (2013)

Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Schattenberg, Jörn M., et al.
Publicado: (2019)

Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Carneros, David, et al.
Publicado: (2020)

Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
por: Parameswaran, Madhangi, et al.
Publicado: (2021)

What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kosmalski, Marcin, et al.
Publicado: (2023)

Laboratory Diagnosis of Antiphospholipid Syndrome in Anticoagulated Patients
por: Tripodi, Armando, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease (Nafld) in obese children- effect of refined carbohydrates in diet
por: Félix, Deise Rosa, et al.
Publicado: (2016)

Fatty Liver Index is a valid predictor of non-alcoholic fatty liver disease (NAFLD) in pregnancy
por: Koralegedara, Iresha Sandamali, et al.
Publicado: (2022)

The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Savic, Dragana, et al.
Publicado: (2020)

Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
por: de Carvalho, Sylene Coutinho Rampche, et al.
Publicado: (2013)

Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar?
por: Longato, Lisa
Publicado: (2013)

Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Saeed, Ali, et al.
Publicado: (2017)

Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort
por: Chalmers, Jane, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19.
por: Bramante, Carolyn T., et al.
Publicado: (2020)

The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Maciejewska-Markiewicz, Dominika, et al.
Publicado: (2021)

Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
por: Yao, Pengyu, et al.
Publicado: (2022)

Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
por: Moghtadaie, Atie, et al.
Publicado: (2023)

Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity
por: Lombardi, Rosa, et al.
Publicado: (2022)

Correction to: Usefulness of Fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity
por: Lombardi, Rosa, et al.
Publicado: (2022)

The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD)
por: Liu, Qing, et al.
Publicado: (2010)

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence
por: Cicero, Arrigo F. G., et al.
Publicado: (2018)

Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
por: Abbas, Tahany, et al.
Publicado: (2020)

Macrophages and scavenger receptors in obesity‐associated non‐alcoholic liver fatty disease (NAFLD)
por: Kragh Petersen, Sine, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease (NAFLD) is associated with dynamic changes in DNA hydroxymethylation
por: Lyall, Marcus J., et al.
Publicado: (2019)

Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Nier, Anika, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9mbf42d5tf89agjqeca2ll8koe